Advances in the Use of Retinoids in Cancer Therapy and Prevention

[1]  B. Dréno,et al.  Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature , 2013, Expert opinion on pharmacotherapy.

[2]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[3]  D. Lorenz,et al.  Retinoids for preventing the progression of cervical intra-epithelial neoplasia. , 2013, The Cochrane database of systematic reviews.

[4]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[5]  A Vacca,et al.  Retinoids: novel immunomodulators and tumour‐suppressive agents? , 2012, British journal of pharmacology.

[6]  V. Nargund,et al.  Management of non-muscle-invasive (superficial) bladder cancer. , 2012, Seminars in oncology.

[7]  A. Pession,et al.  Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma , 2012, Advances in Therapy.

[8]  Zhi Wang,et al.  Clinical trials in chemoprevention of head and neck cancers. , 2012, Reviews on recent clinical trials.

[9]  J. Hara.  Development of treatment strategies for advanced neuroblastoma , 2012, International Journal of Clinical Oncology.

[10]  Edward S. Kim,et al.  Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention , 2012, Clinical Cancer Research.

[11]  M. Cazzaniga,et al.  Fenretinide (4-HPR): A Preventive Chance for Women at Genetic and Familial Risk? , 2012, Journal of biomedicine & biotechnology.

[12]  H. Gronemeyer,et al.  Retinoid receptors and therapeutic applications of RAR/RXR modulators. , 2012, Current topics in medicinal chemistry.

[13]  J. Koo,et al.  A review of the chemopreventative effects of oral retinoids for internal neoplasms. , 2011, Journal of drugs in dermatology : JDD.

[14]  A. Seely,et al.  Vitamin A and Retinoid Derivatives for Lung Cancer: A Systematic Review and Meta Analysis , 2011, PloS one.

[15]  E. Dmitrovsky,et al.  Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models , 2011, Cancer Prevention Research.

[16]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[17]  M. Clagett-Dame,et al.  Vitamin A in Reproduction and Development , 2011, Nutrients.

[18]  Edward S. Kim,et al.  Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients , 2011, Cancer Prevention Research.

[19]  E. Dmitrovsky,et al.  Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and Prevention , 2010, Cancer Prevention Research.

[20]  O. Arrieta,et al.  Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. F. Glass,et al.  Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. , 2010, Journal of drugs in dermatology : JDD.

[22]  R. Góralczyk.  ß-Carotene and Lung Cancer in Smokers: Review of Hypotheses and Status of Research , 2009, Nutrition and cancer.

[23]  R. Nasr,et al.  Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure , 2009, Clinical Cancer Research.

[24]  S. Lippman,et al.  Cancer prevention: from 1727 to milestones of the past 100 years. , 2009, Cancer research.

[25]  Mimi Y. Kim,et al.  Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. , 2009, The American journal of clinical nutrition.

[26]  A. Zelent,et al.  Differentiation therapy of acute myeloid leukemia: past, present and future. , 2009, Current opinion in hematology.

[27]  G. Giaccone,et al.  Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. , 2009, European Journal of Cancer.

[28]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Edward S. Kim,et al.  Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Khuri,et al.  Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Ramlau,et al.  Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Sabichi,et al.  Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer , 2008, Clinical Cancer Research.

[33]  S. Kitareewan,et al.  Cyclin degradation for cancer therapy and chemoprevention , 2007, Journal of cellular biochemistry.

[34]  R. Collins,et al.  Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Sporn,et al.  Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer , 2007, Nature Reviews Cancer.

[36]  M. Puig-Domingo,et al.  Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake , 2007, Journal of endocrinological investigation.

[37]  E. Dmitrovsky,et al.  A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[38]  E. Dmitrovsky,et al.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas , 2007, Proceedings of the National Academy of Sciences.

[39]  G. Lodi,et al.  Interventions for treating oral leukoplakia. , 2006, The Cochrane database of systematic reviews.

[40]  E Marubini,et al.  Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  E. Dmitrovsky,et al.  Bexarotene and erlotinib for aerodigestive tract cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  N. Saba,et al.  Retinoids as chemoprevention for head and neck cancer: where do we go from here? , 2005, Critical reviews in oncology/hematology.

[43]  S. Fosså,et al.  Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Niles.  Signaling pathways in retinoid chemoprevention and treatment of cancer. , 2004, Mutation research.

[45]  M. Sporn,et al.  Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy , 2004, Clinical Cancer Research.

[46]  S. Loening,et al.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  E. Dmitrovsky,et al.  Retinoids in cancer therapy and chemoprevention: promise meets resistance , 2003, Oncogene.

[48]  S. Kitareewan,et al.  Retinoid target genes in acute promyelocytic leukemia , 2003, Leukemia.

[49]  S. Parmar,et al.  Acute promyelocytic leukaemia:a review. , 2003, Expert opinion on pharmacotherapy.

[50]  R. Newton,et al.  Treatment of Kaposis sarcoma in HIV‐1 infected individuals with emphasis on resource poor settings , 2003 .

[51]  Susan M. Chang,et al.  Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Katherine C. Sexton,et al.  The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[53]  F. Recchia,et al.  Ifosfamide, cisplatin, and 13‐Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck , 2001, Cancer.

[54]  Dan Liu,et al.  Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  R. Figlin,et al.  Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  S. Lippman,et al.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. , 2001, Journal of the National Cancer Institute.

[57]  L. Schwartz,et al.  Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  O. Dalesio,et al.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. , 2000, Journal of the National Cancer Institute.

[59]  M. Sporn,et al.  Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 1999, Journal of the National Cancer Institute.

[60]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[61]  E. Dmitrovsky,et al.  Retinoic Acid Promotes Ubiquitination and Proteolysis of Cyclin D1 during Induced Tumor Cell Differentiation* , 1999, The Journal of Biological Chemistry.

[62]  H. Moriwaki,et al.  Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. , 1999, The New England journal of medicine.

[63]  E. Dmitrovsky,et al.  Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. , 1999, Journal of the National Cancer Institute.

[64]  D. Alberts,et al.  13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. , 1998, Gynecologic oncology.

[65]  D. Alberts,et al.  Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[66]  E. Dmitrovsky,et al.  Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Lippman,et al.  Retinoid‐interferon therapy of solid tumors , 1997, International journal of cancer.

[68]  W. Yung,et al.  Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[70]  J. Manson,et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. , 1996, The New England journal of medicine.

[71]  D. Alberts,et al.  Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. , 1994, Journal of the National Cancer Institute.

[72]  M Buyse,et al.  Adjuvant treatment of stage I lung cancer with high-dose vitamin A. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[74]  R. Tarone,et al.  Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. , 1988, The New England journal of medicine.

[75]  D. Alberts,et al.  Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial , 1988, Investigational New Drugs.

[76]  W. Hong,et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.

[77]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[78]  S. Wolbach,et al.  TISSUE CHANGES FOLLOWING DEPRIVATION OF FAT-SOLUBLE A VITAMIN , 1925, The Journal of experimental medicine.

[79]  Edward S. Kim,et al.  Personalizing lung cancer prevention through a reverse migration strategy. , 2013, Topics in current chemistry.

[80]  Tae Yong Kim,et al.  Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. , 2009, Endocrine journal.

[81]  E. Garattini,et al.  Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. , 2007, Vitamins and hormones.

[82]  J. Curtin,et al.  Retinoid target gene activation during induced tumor cell differentiation: human embryonal carcinoma as a model. , 2003, The Journal of nutrition.

[83]  L. Camacho.  Clinical applications of retinoids in cancer medicine. , 2003, Journal of biological regulators and homeostatic agents.

[84]  R. Lotan,et al.  Retinoids and their receptors in cancer development and chemoprevention. , 2002, Critical reviews in oncology/hematology.

[85]  E. Dmitrovsky,et al.  Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  R Cox,et al.  The multi-step nature of carcinogenesis and the implications for risk analysis. , 1998, International journal of radiation biology.

[87]  U. Studer,et al.  Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. , 1995, European urology.

[88]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[89]  R. Mehta,et al.  Distribution of fenretinide in the mammary gland of breast cancer patients. , 1991, European journal of cancer.

[90]  O. Alfthan,et al.  Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. , 1983, European urology.